Fc-optimized GITR antibody boosts CD4 T cell–dendritic cell teamwork against tumors

A new study published in Nature Cancer (搜索)搜索该词条 describes the development of an Fc-optimized antibody targeting glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR (搜索)搜索该靶点) that substantially enhances antitumor immunity by strengthening a specific cellular dialogue between CD4 T cells and dendritic cells. The research, led by Yuval Avraham, Neta Barth, Tomer Yair Bar-On and colleagues, offers a mechanistic explanation for why earlier generations of GITR agonists underperformed in clinical trials and demonstrates how antibody engineering—rather than simply increasing receptor stimulation—can convert a disappointing immunotherapy target into a potent driver of tumor rejection.

GITR (搜索)搜索该靶点 is a costimulatory receptor belonging to the tumor necrosis factor receptor superfamily, expressed at high levels on activated T cells and, to a lesser degree, on regulatory T cells and certain innate immune populations. Engagement of GITR by its ligand, GITRL, delivers costimulatory signals that promote T cell proliferation, survival, and effector function while simultaneously undermining the suppressive capacity of regulatory T cells. These properties made GITR an attractive target for cancer (搜索)搜索该疾病 immunotherapy, and multiple agonistic antibodies entered clinical evaluation in combination with checkpoint inhibitors such as anti–PD-1. However, the clinical results were consistently disappointing: despite encouraging activity in mouse models, human trials of first-generation GITR agonists failed to demonstrate meaningful efficacy.

Fc engineering dictates antitumor activity

The central insight of the work concerns the fragment crystallizable (Fc) region of the antibody. Agonistic antibodies against TNF receptor superfamily members can engage Fc gamma receptors (FcγRs) expressed on myeloid cells, and the nature of this engagement—activating versus inhibitory, high-affinity versus low-affinity—profoundly shapes the biological outcome. The team engineered an anti-GITR antibody (搜索)搜索该药品 with an Fc domain optimized for selective interaction with specific activating Fc gamma receptors while minimizing engagement of the inhibitory receptor FcγRIIB.

The investigators generated a panel of human Fc variants with predetermined binding affinities to the different human FcγRs. This panel consisted of a wild-type IgG1, an aglycosylated IgG1-N297A mutant lacking the ability to engage hFcγRs, an afucosylated IgG1-Fc (aFuc) with selectively enhanced binding to activating hFcγRIIIa, an IgG1-G236A mutant with selectively enhanced binding to activating hFcγRIIa, and an IgG1-G237D;P238D;H268D;P271G;A330R mutant (V11) with selectively enhanced binding to the inhibitory hFcγRIIb. Importantly, these Fc modifications did not affect Fab-mediated GITR (搜索)搜索该靶点-binding affinity.

In mice with established MC38 colon adenocarcinoma tumors, the Fc variants produced significant differences in antitumor efficacy. The Fc-dysfunctional N297A variant triggered only a mild but significant activity, while the V11 variant—which enhances binding to the inhibitory FcγRIIb—did not significantly inhibit tumor growth. In contrast, the G236A and aFuc variants, which enhance binding to activating FcγRIIa (搜索)搜索该靶点 or FcγRIIIa (搜索)搜索该靶点 respectively, significantly increased antitumor potency and extended animal survival. The therapeutic potency of anti-GITR (搜索)搜索该靶点 mAbs in primary tumors directly correlated with the Fc-binding affinity ratio of activating to inhibitory hFcγRs.

A dual-activating Fc scaffold outperforms clinical GITR agonists

Because both aFuc and G236A variants similarly increased antitumor activity, the researchers generated an additional Fc variant carrying both the G236A substitution and reduced fucosylation in its core Fc glycan—termed "GA-aFuc"—to enhance binding to both activating hFcγRIIa and hFcγRIIIa simultaneously. In mice bearing advanced MC38 tumors (approximately 115 mm³), the GA-aFuc variant demonstrated the highest efficacy, implying that enhanced binding to both activating receptors provides a significant therapeutic benefit over either FcγR alone.

The team then compared the GA-aFuc variant's potency to that of commonly used IgG scaffolds of clinical GITR (搜索)搜索该靶点 agonists, including N297A (TRX518) and various IgG1 scaffolds (MK-4166, REGN6569, BMS-986156, GWN323, AMG228 and INCAGN0187). Treating advanced MC38 tumor-bearing mice with the GA-aFuc variant resulted in significant antitumor potency (5/9 tumor-free mice) compared to N297A (0/9 tumor-free mice) and IgG1 (1/9 tumor-free mice). This superior potency was also observed in B16 melanoma, where GA-aFuc—but not IgG1 or N297A—significantly reduced tumor growth. In advanced MCA-205 fibrosarcoma, GA-aFuc and IgG1 exhibited similar potency, superior to N297A, implying a lower Fc-mediated potency threshold in this more immunogenic model.

Dendritic cells mediate the therapeutic effect

Both IgG1 and the GA-aFuc Fc variant showed similar Treg depletion despite the superior therapeutic activity of the latter, indicating an additional FcγR-mediated mechanism. Analysis of FCGR2A and FCGR3A gene expression in the tumor microenvironment revealed that dendritic cell (DC) subsets mainly expressed FCGR2A, NK cells expressed FCGR3A, and macrophages expressed high levels of both. Treatment with the Fc-optimized GA-aFuc variant increased DC activation and frequencies in tumors and draining lymph nodes compared to IgG1 or the Fc-dysfunctional N297A variant.

Using genetic models with DC deficiencies, the researchers demonstrated that tumor growth suppression was abolished when conventional DCs were depleted in tumor-bearing ZBTB46-DTR and XCR1-iDTR mice shortly before anti-GITR (搜索)搜索该靶点 treatment. These results support that cDCs, particularly cDC1, are necessary and sufficient for the antitumor Fc-mediated mechanism of anti-GITR mAbs. Single-cell RNA sequencing of cDC1, cDC2 and mregDC populations revealed that GA-aFuc-associated DCs upregulated genes linked to type I IFN responses, FcγR engagement, antigen processing and MHC I and II presentation, phagocytosis, and migration.

CD4 T cell–dendritic cell crosstalk enables the therapeutic effect

The researchers identified the GITR (搜索)搜索该靶点-positive immune cell types stimulated by DCs upon anti-GITR mAb treatment. Depletion of CD4+ T cells—but not CD8+ T cells or NK cells—abolished the treatment effect on Treg depletion and DC activation. GA-aFuc treatment under CD4+ T cell-depleting conditions did not provide added benefit in controlling tumor growth, whereas treatment under CD8+ T cell-depleting conditions worsened tumor growth control. These findings suggest that the GA-aFuc anti-GITR mAb harnesses CD4+ T cells through its DC-mediated mechanism.

Imaging flow cytometry revealed increased frequencies of myeloid–T cell doublets in the draining lymph nodes of Fc-optimized mAb-treated mice. The doublet formation consisted of CD4+ T cell–cDC2 and CD4+ T cell–macrophage pairs. Only GA-aFuc was located on DCs, while both Fc variants were similarly located on T cells, indicating Fab-mediated binding to T cells and Fc-mediated binding to DCs. GA-aFuc—but not N297A—was located at the interacting membrane surfaces of the DC–T cell doublets, implying physical bridging between FcγR+ DCs and GITR (搜索)搜索该靶点+ T cells by the Fc-enhanced GITR mAb.

Cytotoxic CD4 T cells and Treg depletion

Single-cell RNA sequencing of CD4+ T cells in the tumor microenvironment following treatment with the Fc-optimized anti-GITR (搜索)搜索该靶点 mAbs revealed an intrinsic cytotoxic program, with upregulation of Gzma, Gzmb, Prf1 and Nkg7. CD4+CD25+ and CD8+ T cells isolated from Fc-optimized variant-treated mice exhibited significantly increased cancer (搜索)搜索该疾病-cell-killing capacity, an effect that was antigen-specific and MHC II dependent. The superior cancer-cell-killing activity of CD4+ T cells was lost when physically separated from cancer cells, indicating contact-dependent killing.

The Fc-optimized GITR (搜索)搜索该靶点 mAb also increased Treg depletion in the tumor microenvironment. Tregs were not depleted after treatment with the Fc-dysfunctional N297A variant, indicating the requirement of activating FcγR pathways for Treg targeting. Notably, Treg depletion was selective to the tumor and absent in the draining lymph nodes and spleen. The activated and TH-1-like Treg subpopulations—reported as the most functionally suppressive and correlated with immune checkpoint blockade resistance—were selectively eliminated by the Fc-active variants.

Therapeutic activity is independent of GITR agonism

To investigate how GITR (搜索)搜索该靶点 agonism contributes to the improved antitumor response, the researchers generated a version of the Fc-optimized mAb with weakened agonism, using a bispecific antibody format with a monovalent GITR-binding arm. The weakened agonistic variant demonstrated comparable dose-dependent Treg reduction and DC activation to the agonist mAb, indicating that Treg depletion and DC activation are Fc dependent rather than reliant on GITR agonism. Intriguingly, the weakened agonistic variant suppressed tumor growth to a greater extent than the agonistic variant, suggesting that the therapeutic activity of the Fc-optimized anti-GITR mAbs in situ is independent of GITR agonism.

Implications for the immunotherapy pipeline

The engineering logic carries broader implications for the immunotherapy pipeline. Antibodies targeting OX40, CD137 (4-1BB), CD27, and other costimulatory TNF receptors have followed a similar trajectory—striking preclinical activity followed by clinical underperformance—and several groups have independently converged on the conclusion that Fc receptor engagement and valency are decisive variables. The Nature Cancer (搜索)搜索该词条 study provides one of the most complete mechanistic accounts of how these variables operate in the specific context of CD4 T cell–dendritic cell biology.

From a translational standpoint, the crosstalk amplified by the optimized antibody is mechanistically complementary to checkpoint blockade: anti–PD-1 reinvigorates exhausted cytotoxic T cells, whereas the Fc-optimized anti-GITR antibody (搜索)搜索该药品 expands and licenses the helper and antigen-presenting cell axis that supplies those cytotoxic cells. The work also provides biomarkers for patient selection: tumors rich in dendritic cells and CD4 T cell infiltration—the so-called immune-inflamed phenotype—are the most likely to benefit, whereas "cold" tumors lacking this cellular infrastructure may require priming strategies before GITR (搜索)搜索该靶点 agonism can be effective.

Safety considerations remain central to any costimulatory agonist program. Systemic GITR (搜索)搜索该靶点 activation carries risks of autoimmune-like pathology and nonspecific T cell activation, and first-generation clinical candidates were dose-limited by cytokine-related toxicities. The Fc-optimized design mitigates these risks by requiring FcγR-mediated presentation for full activity, effectively gating receptor activation to professional antigen-presenting cell niches. Whether human FcγR biology—with its different receptor repertoire and expression patterns compared with mice—will reproduce this selectivity is the central question that clinical testing must answer.